NASDAQ: GLYC Nov 2021 Glycobiology-based therapeutics Transforming lives Harout Semerjian President and CEO © 2021 GlycoMimetics, Inc. All rights reserved. Forward-Looking Statements 2 • To the extent that statements contained in this presentation are not descriptions of historical facts regarding GlycoMimetics, Inc. ("GlycoMimetics," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknow ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2021 Earnings Conference Call November 2, 2021 8:30 AM ET Company Participants Shari Annes - IR Harout Semerjian - CEO, President & Director Eric Feldman - SVP & Chief Medical Officer Brian Hahn - SVP & CFO Conference Call Participants Edward White - H.C. Wainwright & Co. Zegbeh Jallah - ROTH Capital Partners Jiale Song - Jefferies Operator Good morning, and thank you all for joining the GlycoMimetics call. [Operator Instructions]. I would now like to turn the call over ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (State or Other Jurisdiction of Incorporation or Organization) 9708 Medical Center Drive Rockville, Maryland 20850 (Address of principal executive offices) ...

Glycobiology-based therapeutics Transforming lives Harout Semerjian President and CEO NASDAQ: GLYC September 2021 © 2021 GlycoMimetics, Inc. All rights reserved. Forward-Looking Statements • To the extent that statements contained in this presentation are not descriptions of historical facts regarding GlycoMimetics, Inc. ("GlycoMimetics," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and un ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Eric Feldman - Senior Vice President and Chief Medical Officer Brian Hahn - Senior Vice President and Chief Financial Officer Harout Semerjian - President and Chief Executive Officer Conference Call Participants Edward White - H.C. Wainwright Roger Song - Jefferies Operator Good morning, and thank you all for joining GlycoMim ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (State or ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q1 2021 Earnings Conference Call May 3, 2021 8:30 AM ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Brian Hahn - Chief Financial Officer John Magnani - Chief Scientific Officer Eric Feldman - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Zegbeh Jallah - ROTH Capital Partners Steve Bersey - H.C. Wainwright Jason Bouvier - Jefferies Operator Good morning and thank you for joining the GlycoMimetics Ca ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (State or ...

Innovation Today, Healing Tomorrow. March 2021 | --- | --- | --- | |-----------|-------|-------| | | | | | CORPORATE | | | Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding GlycoMimetics, Inc. ("GlycoMimetics," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other fac ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2020 Earnings Conference Call March 2, 2021 8:30 AM ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Brian Hahn - Chief Financial Officer Eric Feldman - Chief Medical Officer (Incoming) Conference Call Participants Zegbeh Jallah - ROTH Capital Partners Stephen Wiley - Stifel Financial Corp. Cynthia Chen - Cowen Inc. Biren Amin - Jefferies Group LLC Operator Good morning and thank you all for joining the GlycoMimetics Call. At ...